Screening of microbial bioactives as potential breast cancer inhibitors: A structure-based multitargeted molecular docking analysis
Journal of Chemical Research · 2026-05 · 50 (3)
DOI: 10.1177/17475198261448924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Research, online erschienen am 22.05.2026. Verfasst von Al Nahian Joy und 12 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Breast cancer still ranks among the top causes of death globally; therefore, new therapeutic agents are urgently needed. Microbe-derived bioactive compounds present great promise for novel drug discovery. Considering this, the study aims to evaluate their binding affinity, efficacy, bioavailability, and toxicity against key breast cancer target proteins. Molecular docking was performed on 80 bacterial compounds against six breast cancer targets (Human Epidermal Growth Factor Receptor 2 ( HER2 ), Estrogen Receptor Alpha ( ERα ), B-Cell Lymphoma 2 ( BCL2 ), Breast Cancer Gene 1 ( BRCA1 ), Breast Cancer Gene 2 ( BRCA2 ), and Peroxisome Proliferator–Activated Receptor Gamma ( PPARG )). Lead compounds were identified through molecular docking, the Lipinski rule of five, and toxicity profiling. Molecular dynamics simulations assessed the stability and dynamics of top ligand–protein complexes. In addition, a comparative analysis against known phytochemicals or drugs for breast cancer was performed. Eighteen microbial compounds showed strong binding affinities with multiple proteins. Marfuraquinocin A and Marfuraquinocin D were identified as promising candidates due to their favorable pharmacokinetic and safety profiles. Molecular dynamics simulations confirmed the structural stability of the top docked complexes, with minimal root mean square deviation fluctuations. Besides, comparative evaluation showed significant differences in binding affinities between microbial bioactives and known phytochemicals or drugs. The results suggest that microbial bioactives, particularly Marfuraquinocin A and Marfuraquinocin D, can potentially be effective breast cancer inhibitors. Future in vitro and in vivo experiments are recommended to confirm their therapeutic effectiveness and safety.
Zitieren
APA
Joy, A. N., Khan, M., Alam, S. M. S., Shehreen, N., Hasan, W., Oishe, R. A., Islam, S. M. B. U., Rahman, K. M. M., Bulbul, N., Jime, J. S., Shishir, M. A., Safa, A., & Fakruddin, M. (2026). Screening of microbial bioactives as potential breast cancer inhibitors: A structure-based multitargeted molecular docking analysis. Journal of Chemical Research, 50(3). https://doi.org/10.1177/17475198261448924
Vancouver
Joy AN, Khan M, Alam SMS, Shehreen N, Hasan W, Oishe RA, et al. Screening of microbial bioactives as potential breast cancer inhibitors: A structure-based multitargeted molecular docking analysis. Journal of Chemical Research. 2026;50(3). doi:10.1177/17475198261448924
BibTeX
@article{Joy2026,
author = {Joy, Al Nahian and Khan, Marua and Alam, S. M. Shahriar and Shehreen, Nasiha and Hasan, Wahidul and Oishe, Ritika Amin and Islam, S. M. Bakhtiar Ul and Rahman, Kazi Md. Mostafizur and Bulbul, Nayeema and Jime, Jinath Sultana and Shishir, Md. Asaduzzaman and Safa, Ashrafus and Fakruddin, Md.},
title = {Screening of microbial bioactives as potential breast cancer inhibitors: A structure-based multitargeted molecular docking analysis},
journal = {Journal of Chemical Research},
year = {2026},
volume = {50},
number = {3},
doi = {10.1177/17475198261448924}
}
EUVIMED